Literature DB >> 16706987

Human endothelial cells synthesize and release ADAMTS-13.

N Turner1, L Nolasco, Z Tao, J-F Dong, J Moake.   

Abstract

Hepatic stellate cells have been considered to be a primary source for human plasma ADAMTS-13, the von Willebrand factor (VWF)-cleaving metalloprotease. In this study, ADAMTS-13 antigen was detected by immunofluorescence in both venous (HUVECs) and arterial endothelial cells (HUAECs) using both polyclonal antibodies made against peptides found in various domains of human ADAMTS-13, as well as by a monoclonal antibody against the ADAMTS-13 metalloprotease domain. ADAMTS-13 antigen had an intra-cellular distribution in endothelial cells distinct from the Weibel-Palade body location of VWF, and was released from the cells during 48 h in culture. The mRNA for ADAMTS13 was detected in HUVECs and HUAECs using reverse transcription-polymerase chain reaction (RT-PCR), indicating that the enzyme is synthesized in these cells. The ADAMTS-13 protein was immunoprecipitated from HUVECs and had an approximate M(r) of 170 kDa, similar to the molecular mass of recombinant ADAMTS-13. The ADAMTS-13 in HUVEC and HUAEC lysates had enzymatic activity using both static and flow assays. We conclude that ADAMTS-13 is synthesized in human endothelial cells, and released constitutively. The vast number of endothelial cells in the body may be an important source of ADAMTS-13.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16706987     DOI: 10.1111/j.1538-7836.2006.01959.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  56 in total

1.  The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.

Authors:  Rens de Groot; David A Lane; James T B Crawley
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

Review 2.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

3.  Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.

Authors:  Masami Niiya; Masayuki Endo; Dezhi Shang; Philip W Zoltick; Nidal E Muvarak; Wenjing Cao; Sheng-Yu Jin; Christopher G Skipwith; David G Motto; Alan W Flake; X Long Zheng
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

4.  Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation.

Authors:  Manabu Horii; Shiro Uemura; Masahito Uemura; Masanori Matsumoto; Hiromichi Ishizashi; Keiichi Imagawa; Hajime Iwama; Yukiji Takeda; Hiroyuki Kawata; Tamio Nakajima; Yoshihiro Fujimura; Yoshihiko Saito
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

5.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 6.  Diverse activities of von Willebrand factor in traumatic brain injury and associated coagulopathy.

Authors:  Xin Xu; Rosemary Kozar; Jianning Zhang; Jing-Fei Dong
Journal:  J Thromb Haemost       Date:  2020-10-06       Impact factor: 5.824

Review 7.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 8.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

9.  N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity.

Authors:  Wenhua Zhou; Han-Mou Tsai
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

Review 10.  Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.